EGFR gene mutation and treatment (EGFR gene mutant lung cancer)
EGFR gene mutation refers to changes in the EGFR gene sequence, leading to abnormal gene activity and thus triggering disease and inhibiting cell growth. EGFR-mutant lung cancer is most common in non-small cell lung cancer (NSCLC) patients, especially adenocarcinoma patients. Therefore, EGFR gene mutation can be used as an indicator for lung cancer detection. In lung adenocarcinoma patients, EGFR gene mutations can occur at many gene loci (i.e., gene coordinates), with common loci located primarily in exons 18 to 21 of the tyrosine kinase region. Mutations in exons 19 and 21 are more severe, especially exon 19 mutations, which are generally considered to be more effective with molecularly targeted therapies.
For patients with lung cancer diagnosed with EGFR gene mutations, clinically, molecularly targeted drugs can target small molecule inhibitors of the mutated EGFR gene. These inhibitors can suppress the activity of the mutated gene, thereby killing cancer cells and achieving the goal of cancer treatment. Small molecule inhibitors targeting EGFR gene mutations have significantly improved the treatment outcomes of lung cancer and prolonged patient survival, representing a major breakthrough in the treatment of non-small cell lung cancer.
Targeted drugs for the treatment of EGFR mutant lung cancer：
Currently approved drugs for the treatment of EGFR mutant lung cancer include：
The first generation of Gefitinib and Erlotinib;
The second generation Dacomitinib and Afatinib;
The third generation Osimertinib and Mobocetinib have better clinical efficacy and lower toxicity.
FAQ
What isEGFR Gene mutation， Why is it related to lung cancer?
EGFR Gene mutation It refers to changes in the sequence of epidermal growth factor receptor genes, leading to abnormal gene activity and promoting abnormal cell growth. This mutation is closely related to non-small cell lung cancer (NSCLC), especially lung adenocarcinoma, and can serve as an important indicator for detecting and treating lung cancer.
EGFR Gene mutation What are the common loci?
EGFR Gene mutation It mainly occurs in exons 18-21 of the tyrosine kinase region, with mutations in exons 19 and 21 being the most common and severe, especially in patients with positive mutations in exon 19 who usually respond well to targeted drug therapy.
What are the treatment options for EGFR gene-mutated lung cancer?
EGFR Gene mutated lung cancer The main treatment method is to use targeted drugs (small molecule inhibitors). These drugs are specifically designed to target mutations EGFR Gene suppression, including first generation (such as gefitinib), second generation (such as afatinib), and third generation (such as osimertinib), with the latter being more effective and having fewer side effects.
What are the side effects of EGFR targeted drugs?
EGFR Common side effects of targeted drugs include rash, diarrhea, oral ulcers, etc. Compared with the previous two generations, third-generation targeted drugs (such as Axitinib) have relatively mild side effects, but rare serious side effects such as interstitial pneumonia may still occur, and regular check ups should be conducted.
How to detect EGFR gene mutations in lung cancer and other conditions?
Lung cancer Wait, waitEGFR Gene mutation detection Usually completed through tumor tissue biopsy, liquid biopsy (blood test), or cellular examination. Liquid biopsy is a non-invasive examination method that can detect free radicals from the blood DNA， Suitable for patients who are unable to undergo organizational examinations.